-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314

Benzinga·11/16/2026 20:28:32
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $303 to $314.